Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin
Personalized Medicine, Ahead of Print. (Source: Future Medicine: Personalized Medicine)
Source: Future Medicine: Personalized Medicine - April 29, 2024 Category: Genetics & Stem Cells Authors: Xiang Zhang Qi Yuan Dawei Zhang Source Type: research
Aspirin Use and Management of Breast Cancer
The Alliance trial led by Chen and colleagues and published in this issue of JAMA addresses an important topic in the management of breast cancer: can daily use of 300 mg of aspirin improve invasive disease –free survival among persons with a diagnosis of nonmetastatic, high-risk breast cancer? The answer is a fairly definitive no based on prespecified futility rules in a rigorous phase 3, randomized, placebo-controlled, double-blind trial. The trial (A011502) enrolled 3020 persons (3004 women [99.5% ] and 16 men [0.5%]) from 534 academic and community sites across the US and Canada. Although the trial was planned for 5 ...
Source: JAMA - Journal of the American Medical Association - April 29, 2024 Category: General Medicine Source Type: research
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
This study examines the potential benefits of aspirin as adjuvant therapy for survivors of early breast cancer. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 29, 2024 Category: General Medicine Source Type: research
Blending polydopamine-derived imprinted polymers with rice straw-based fluorescent carbon dots for selective detection and adsorptive removal of ibuprofen
Int J Biol Macromol. 2024 Apr 25:131765. doi: 10.1016/j.ijbiomac.2024.131765. Online ahead of print.ABSTRACTDual-functioning probes capable of detecting and removing hazardous substances have recently received increased attention compared to exclusive sensory probes. Herein, a new composite is synthesized by blending polydopamine imprinted polymers with fluorescent carbon dots (PIP-FCDs) for the selective recognition and adsorption of Ibuprofen (IBF), which is a nonsteroidal anti-inflammatory drug and is excessively released in the pharmaceutical wastes. The PIP-FCDs consist of confined pockets for encasing IBF and generat...
Source: International Journal of Biological Macromolecules - April 27, 2024 Category: Biochemistry Authors: Irshad Mohiuddin Raghubir Singh Varinder Kaur Source Type: research
An Inevitable Challenge in Primary Prevention of Upper Gastrointestinal Bleeding Among Aspirin Users: Appropriate Use of Proton Pump Inhibitors
Li et al1 conducted a retrospective observational study using the Nationwide Emergency Department Sample, demonstrating an increased incidence of upper gastrointestinal bleeding among patients on long-term aspirin therapy without cardiovascular disease. Considering the rising incidence, severity, and costs associated with upper gastrointestinal bleeding among patients using aspirin for primary cardiovascular prevention, the authors conclude that there is a need for cautious discussion beyond current guidelines regarding the indications for aspirin use. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - April 27, 2024 Category: General Medicine Authors: Hiroshi Ito Tags: Letter Source Type: research
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review
Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149.ABSTRACTMelatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive due to the heterogeneity of the studies. A personalized approach to testing clinical parameters and response to integrative treatment with nontoxic an...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Eugeniy Smorodin Valentin Chuzmarov Toomas Veidebaum Source Type: research
Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318 (Source: Vascular)
Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review
Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149.ABSTRACTMelatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive due to the heterogeneity of the studies. A personalized approach to testing clinical parameters and response to integrative treatment with nontoxic an...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Eugeniy Smorodin Valentin Chuzmarov Toomas Veidebaum Source Type: research
Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318 (Source: Vascular)
Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review
Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149.ABSTRACTMelatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive due to the heterogeneity of the studies. A personalized approach to testing clinical parameters and response to integrative treatment with nontoxic an...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Eugeniy Smorodin Valentin Chuzmarov Toomas Veidebaum Source Type: research
Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318 (Source: Vascular)
Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review
Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149.ABSTRACTMelatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive due to the heterogeneity of the studies. A personalized approach to testing clinical parameters and response to integrative treatment with nontoxic an...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Eugeniy Smorodin Valentin Chuzmarov Toomas Veidebaum Source Type: research
Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318 (Source: Vascular)
Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review
Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149.ABSTRACTMelatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive due to the heterogeneity of the studies. A personalized approach to testing clinical parameters and response to integrative treatment with nontoxic an...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Eugeniy Smorodin Valentin Chuzmarov Toomas Veidebaum Source Type: research
Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318 (Source: Vascular)
Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research
